Ethicon breaks into Chinese suture market:
This article was originally published in Clinica
Scotland-based Ethicon, a subsidiary of Johnson & Johnson (US), has won a £0.25 million ($0.39 million) order from China for 22,000 sutures. The company sees the purchase as launching its entry into a market which could be worth "tens of millions of pounds" by 2004. According to distribution manager Jim Milligan: "One of the keys to breaking into the Chinese market has been giving them exactly what they require, including the instructions in Mandarin on all the packaging. Doing this in Edinburgh was far from easy but we have been assured the Chinese characters say what they are supposed to." Ethicon also intends to start manufacturing in Shanghai within 18-24 months.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.